The content of this presentation is provided to an audience of international healthcare professionals for scientific discussion and scientific exchange. Bayer does not recommend the use of any drug substance outside of its approved indications.

At the moment of publication, the compound presented has been only approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA). For other approvals, follow your local regulations or health authorities legislation.

American Diabetes Association 
83rd Scientific Sessions 23-26 June

Scientific publications at ADA 83rd Scientific Sessions 2023.

Thank you for your interest! Please see below to download the posters/presentations at ADA Scientific Sessions 2023. Presentations, Videos and Posters will be available following the presentation at the congress.

Some of the links to view the Presentations or Posters will link to the official ADA Scientific Sessions 2023 web page. You may need to be a registered delegate and logged in the respective platform to view the content.

Finerenone

Saturday June 24, 2023; 11:30 AM – 12:30 PM             
Prevalence of Chronic Kidney Disease Associated With Type 1 Diabetes in the US

Session: Epidemiology - Type 1 Diabetes 

Lead Author: Peter Rossing

Doc Icon

Download the Slide Deck

Sunday Jun 25, 2023; 11:30 AM- 12:30 PM PM              
Outcomes with Finerenone in People with CKD and T2D by Baseline Insulin Resistance: A FIDELITY Subgroup Analysis

Session: Clinical Therapeutics—Other Therapeutic Agents

Lead Author: Thomas Ebert 

Doc Icon

Download the Slide Deck

Monday Jun 26, 2023; 11:30 AM - 12:30 PM PM                
Efficacy of Finerenone in Patients With Abnormal Markers of Liver Steatosis and Fibrosis: A FIDELITY Subgroup Analysis

Session: Complications—Kidney—Clinical and Translational Research

Lead Author: Nikolaos Perakakis

Doc Icon

Download the Slide Deck
Finerenone: a new approach to kidney protection in patients with type 2 diabetes


Saturday 17 June, 2023 | 13.35 - 13.45 CET | On Demand
Non-steroidal MRAs: A new pillar of treatment for cardiorenal protection in CKD and T2D
The symposium offers a unique opportunity to gain an overview of the most recent guideline updates related to CKD and T2D and the need for a comprehensive and holistic approach to the patient management. To discuss the use of the ‘pillar approach’ to manage CKD in T2D and how to use finerenone in clinical practice based on expert experience. To highlight the relevance of the urgency to treat CKD in T2D to improve cardiorenal outcomes.

Faculty: Giuseppe Grandaliano (chair), Beatriz Fernandez, Christoph Wanner, Rajiv Agarwal Session: Industry Sponsored Symposium Speaker: Rajiv Agarwal

Play Icon

View Video

17/06/2023 - 8:30 - 9:45 CEST

FINEGUST- Japan; characteristics of medication-initiator cohorts of patients with chronic kidney disease and type 2 diabetes in Japan - a report from FOUNTAIN platform

Session type: focused oral presentation ROOM 6 Presenter: Yuichiro Yano

Play Icon

Visit Link to View Video
Doc Icon

Download the Slide Deck

16/06/2023 - 08:30-09:45 CEST

Validation of a CKD progression risk prediction model in the FIDELITY trial population

Session type: poster / abstract Presenter: Navdeep Tangri

Play Icon

Visit Link to View Video
Doc Icon

Download the Slide Deck

17/06/2023 - 14:45 - 16:00 CEST

REKA: Incidence and frequencies of hyperkalemia in patients with chronic kidney disease: a retrospective database study from US clinical care

Session type: focused oral presentation ROOM 1 Presenter: Van Boemmel-Wegmann

Play Icon

Visit Link to View Video
Doc Icon

Download the Slide Deck

The compendium provided by Bayer is a compilation of Bayer-sponsored presentations. Copies of presentations obtained from this compendium are for personal use only and may not be reproduced or distributed without permission from the American Diabetes Association (ADA) and from the authors.

 

The content of this presentation is provided to an audience of international healthcare professionals for scientific discussion and scientific exchange. Bayer does not recommend the use of any drug substance outside of its approved indications.

At the moment of publication, the compound presented has been only approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA). For other approvals, follow your local regulations or health authorities legislation.

The European Society of Cardiology
Annual Congress 25-28 August 2023

Scientific publications at ESC Annual Congress 2023.

Thank you for your interest! Please see below to download the posters/presentations at ESC 2023. Presentations, Videos and Posters will be available following the presentation at the congress.

Some of the links to view the Presentations or Posters will link to the official ESC 2023 web page. You may need to be a registered delegate and logged in the respective platform to view the content.

Finerenone

August 28, 8.30-10.00 (9.06); Room Riga
Effect of finerenone in patients with chronic kidney disease and type 2 diabetes by baseline anaemia status: A FIDELITY analysis

Session: Advances in Science Presentation, Novel targets and treatments for heart diseases and diabetes Lead author: Ajay Singh

Doc Icon

Download the Slide Deck

August 28, 8.30-10.00 (9.42); Room Riga
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by diuretic use: A FIDELITY analysis

Session: Advances in Science Presentation, Novel targets and treatments for heart diseases and diabetes Lead author: Robert Mentz

Doc Icon

Download the Slide Deck

August 25, 15.15-16.00, Station 9
Acute over-additive natriuretic effects by a combination of finerenone and SGLT2 inhibition in rats with an activated renin-angiotensin-aldosterone system: a mechanistic basis for clinical outcomes?

Session: Improving outcomes in heart failure: bench to bedside Lead author: Peter Kolkhof

Doc Icon

Download the Slide Deck
Finerenone: a new approach to kidney protection in patients with type 2 diabetes


Saturday 17 June, 2023 | 13.35 - 13.45 CET | On Demand
Non-steroidal MRAs: A new pillar of treatment for cardiorenal protection in CKD and T2D
The symposium offers a unique opportunity to gain an overview of the most recent guideline updates related to CKD and T2D and the need for a comprehensive and holistic approach to the patient management. To discuss the use of the ‘pillar approach’ to manage CKD in T2D and how to use finerenone in clinical practice based on expert experience. To highlight the relevance of the urgency to treat CKD in T2D to improve cardiorenal outcomes.

Faculty: Giuseppe Grandaliano (chair), Beatriz Fernandez, Christoph Wanner, Rajiv Agarwal Session: Industry Sponsored Symposium Speaker: Rajiv Agarwal

Play Icon

View Video

17/06/2023 - 8:30 - 9:45 CEST

FINEGUST- Japan; characteristics of medication-initiator cohorts of patients with chronic kidney disease and type 2 diabetes in Japan - a report from FOUNTAIN platform

Session type: focused oral presentation ROOM 6 Presenter: Yuichiro Yano

Play Icon

Visit Link to View Video
Doc Icon

Download the Slide Deck

16/06/2023 - 08:30-09:45 CEST

Validation of a CKD progression risk prediction model in the FIDELITY trial population

Session type: poster / abstract Presenter: Navdeep Tangri

Play Icon

Visit Link to View Video
Doc Icon

Download the Slide Deck

17/06/2023 - 14:45 - 16:00 CEST

REKA: Incidence and frequencies of hyperkalemia in patients with chronic kidney disease: a retrospective database study from US clinical care

Session type: focused oral presentation ROOM 1 Presenter: Van Boemmel-Wegmann

Play Icon

Visit Link to View Video
Doc Icon

Download the Slide Deck

The compendium provided by Bayer is a compilation of Bayer-sponsored presentations. Copies of presentations obtained from this compendium are for personal use only and may not be reproduced or distributed without permission from the European Society of Cardiology (ESC) and from the authors.

 

© 2023 Bayer AG

The content of this presentation is provided to an audience of international healthcare professionals from around the world for scientific discussion and scientific exchange. Bayer does not recommend the use of any drug substance outside of its approved indications.

 

At the moment of publication, the compound presented has been only approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA). For other approvals, follow your local regulations or health authorities legislation.

 

  • MA-M_FIN-ALL-1474-1

Last updated on 14/11/2023